Rapid Synthesis of Plasmids and Mutagensis - JCVI

The contract involves the renewal of a prior agreement awarded in the fourth quarter of fiscal year 2023, focusing on the rapid synthesis of plasmids and mutagenesis for the Joint Center for Virology and Immunology (JCVI). Specific details from the original award are not available, but this renewal continues the work under the oversight of the Centers for Disease Control and Prevention (CDC). The contract is forecasted rather than currently active, with no solicitation number or detailed set-aside information provided. The CDC is managing this contract, with Lindsay Culp serving as the primary program point of contact and the contracting officer yet to be determined. The place of performance and detailed organizational information are unspecified. The opportunity remains open for notification via the official industry forecast platform, highlighting its intention to maintain the ongoing scientific work related to plasmid synthesis and mutagenesis crucial for virology research and public health applications.